Core Viewpoint - Garden Biologics announced that its subsidiary, Huayuan Pharmaceutical, has won the bid for Alendronate Sodium Tablets in the 11th batch of national centralized drug procurement organized by the National Drug Procurement Office on November 7 [1] Group 1 - The announcement was made on November 7, coinciding with the release of the procurement results [1] - Alendronate Sodium Tablets are now part of the national centralized procurement, which may impact the company's market position and sales [1]

Core Viewpoint - Garden Biologics' subsidiary, Zhejiang Garden Pharmaceutical Co., Ltd., has been selected in the 11th batch of national centralized drug procurement, which is expected to enhance market penetration and brand influence for the company's Alendronate Sodium Tablets [1] Group 1 - The national centralized procurement results were announced on November 7, indicating that Garden Pharmaceutical's Alendronate Sodium Tablets have been selected [1] - The selection is anticipated to facilitate rapid market expansion and increase market share for the product [1] - This development is expected to promote the growth of the company's pharmaceutical formulation business and enrich its product pipeline [1]

Core Viewpoint - Garden Biologics (300401.SZ) announced that its subsidiary, Zhejiang Garden Pharmaceutical Co., Ltd., has been selected in the 11th batch of national centralized drug procurement, which will enhance the market penetration of its Alendronate Sodium Tablets and promote the development of its pharmaceutical formulation business [1] Group 1 - The selection of Alendronate Sodium Tablets in the national procurement will facilitate rapid market expansion for the product [1] - This development is expected to increase the market share of the product, thereby enriching the company's product pipeline [1] - The outcome will also enhance the brand influence of the company in the pharmaceutical industry [1]

Group 1 - The core point of the article is that Huayuan Biopharmaceutical (300401.SZ) announced that its wholly-owned subsidiary, Zhejiang Huayuan Pharmaceutical Co., Ltd., has been selected for the national centralized procurement of its product, Alendronate Sodium Tablets [1] Group 2 - The product is indicated primarily for the treatment of osteoporosis in postmenopausal women and for increasing bone mass in men with osteoporosis [1]

Group 1 - Garden Biologics announced that its subsidiary, Zhejiang Garden Pharmaceutical Co., Ltd., won the bid for Alendronate Sodium Tablets in the 11th batch of national centralized drug procurement [1] - For the year 2024, the revenue composition of Garden Biologics is projected to be 65.08% from vitamins and 34.92% from the pharmaceutical manufacturing sector [1] - As of the report, the market capitalization of Garden Biologics is 7.5 billion yuan [1]

Core Insights - The company Garden Biologics announced that its wholly-owned subsidiary, Garden Pharmaceuticals, has won the bid for the 11th batch of national centralized drug procurement for its product Alendronate Sodium Tablets [1] - This medication is primarily used for the treatment of osteoporosis in postmenopausal women and men to increase bone mass [1] - The product specifications are 70mg per tablet, with each box containing 4 tablets, and the procurement regions include Inner Mongolia, Jiangsu, Henan, Hunan, and Gansu, with a procurement period lasting until December 31, 2028 [1] Market Impact - Winning this bid will help the product rapidly expand its market presence and increase market share [1] - It will promote the development of the company's pharmaceutical formulation business and further enrich the company's product pipeline [1] - This achievement is expected to enhance the company's brand influence in the industry [1]

证券代码：300401 证券简称：花园生物 公告编号：2025-044 债券代码：123178 债券简称：花园转债 浙江花园生物医药股份有限公司 关于子公司产品中选第十一批全国药品集中采购的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 11月7日国家组织药品联合采购办公室公布了第十一批全国药品集中采购的中选结 果，浙江花园生物医药股份有限公司（以下简称"公司"）全资子公司--浙江花园药业 有限公司（以下简称"花园药业"）产品阿仑膦酸钠片中选本次国家集采。现将相关情 况公告如下： 一、拟中选药品基本情况 | 产品名称 | 适应症 | 规格 | 产品包装 | 供应地区 | 采购周期至 | | --- | --- | --- | --- | --- | --- | | 阿仑膦酸钠片 | 主要为治疗绝经后女性 的骨质疏松症以及治疗 | 70mg | 4片/盒 | 内蒙古、江 苏、河南、 | 2028年12月31日 | | | 男性骨质疏松症以增加 | | | 湖南、甘肃 | | | | 骨量 | | | | | 二、本次中选对公司的影响 花园药业产品阿仑膦酸钠 ...

Core Viewpoint - Garden Bio announced on November 6 that as of October 31, 2025, the total number of shareholders is 28,490 [2] Summary by Category - Company Information - Garden Bio has a total of 28,490 shareholders as of the specified date [2]

Core Viewpoint - The company Garden Bio responded to investor inquiries on November 6, indicating that specific operational details should be monitored through the company's periodic reports [2] Group 1 - The company emphasized the importance of following its disclosed periodic reports for insights into its operational status [2]

Core Viewpoint - The company acknowledges that stock price fluctuations are influenced by multiple factors and emphasizes its commitment to high-quality sustainable development and effective communication with the capital market to maintain its market value [1] Group 1 - The company will continue to enhance its operational management to promote sustainable development [1] - The company aims to strengthen communication and engagement with the capital market [1] - The company recognizes the impact of various factors on stock price volatility [1]